Antiepileptic Drugs Market Opportunity Analysis, Vendor Landscape, Growth, Developments & Forecast 2021-2027
The Antiepileptic Drugs Market is expected to have a highly positive outlook for the next eight years 2021-2027. This Research Reports emphasizes on key industry analysis, market size, Share, growth and extensive industry dynamics with respect to with respect to drivers, opportunities, pricing details and latest trends in the industry.
The global Antiepileptic Drugs Market analysis further provides pioneering landscape of market along with market augmentation history and key development involved in the industry. The report also features comprehensive research study for high growth potential industries professional survey with market analysis. Antiepileptic Drugs Market report helps the companies to understand the market trends and future market prospective,opportunities and articulate the critical business strategies.
Symptomatic epilepsy is caused by infections in the brain, such as meningitis, whereas idiopathic epilepsy is caused by a hereditary disease. The number of anti-epilepsy drugs (AEDs) available has doubled in the last few decades, with nine new therapies approved for the treatment of paediatric epilepsy in the last decade, as the advantages of the medicines outweigh the risks of side effects. CBM are rapidly replacing second and first generation drugs, as they are more safe and tolerable compared to previous generation drugs.
In 2019, the global anti-epileptic medicines market is predicted to be worth US$ 7,155.6 million, growing at a CAGR of 6.6 percent over the forecast period (2019-2027).
Increasing focus of market players on unmet needs of patients with refractory epilepsy is expected to drive growth of the global anti-epileptic drugs market.
The need for innovative AEDs is projected to be fuelled by add-on medicines developed by market players for the treatment of epilepsy with fewer side effects at accessible pricing. Some industry companies, such as Zogenix Inc., INSYS Therapeutics Inc., and Eisai, are involved in the research and development of epilepsy medications. Furthermore, market entrants are entering the market with pipeline medications that are initially pursuing FDA approval as adjunctive therapy in the refractory partial-seizure population, addressing the biggest unmet need among epilepsy patients.
The pipeline medications are currently being developed and are intended to have fewer drug interactions, better side effect profiles, and overall increased safety. This fills a critical need in the anti-epileptic medicine market, as most of the current treatments, such as carbamazepine, valproate, and phenytoin, are efficacious but have poor safety profiles and are poorly tolerated by children.
Global Anti-epileptic Drugs Market – Restraints
In addition to AEDs, complementary and alternative medicine (CAM) such as the ketogenic diet, modified Atkins diet (MAD), and low glycemic index treatment (LGIT) are frequently used to treat epilepsy in children, which is projected to slow market growth. For example, according to the Clinical Nutrition Research (a research study conducted to examine the consumption of nutritional supplements to treat a number of diseases), in 2016, around 30% of the children suffering from uncontrolled epileptic seizures were untreated, worldwide, where ketogenic diet (KD) can be an alternative medical treatment for these children, thus restraining the AED market growth. Furthermore, a lack of evidence about the efficacy of newer, more expensive treatments vs older, less expensive drugs is likely to stymie market expansion over the forecast period.
Global Anti-epileptic Drugs Market – Regional Insights
The global anti-epileptic medicines market is divided into five regions: North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa. Because of the rising prevalence of epilepsy and the introduction of generic medications, North America is likely to dominate the worldwide anti-epileptic pharmaceuticals market. For example, according to the Centers for Disease Control and Prevention, in 2017, around 3.4 million people had active epilepsy in the U.S., which included 3 million adults and 470,000 children. In addition, in August 2019, Dr. Reddy’s Laboratories launched generic anti-epileptic Vigabatrin powder, an oral solution in the U.S. market for the treatment of partial seizure.
Due to increased product launches by key players in the region, Asia Pacific is predicted to be the fastest expanding region in the worldwide anti-epileptic medicines market. For example, Eisai Co., Ltd. developed Fycompa, an antiepileptic medication (AED) in February 2020 for the adjunctive treatment of partial onset seizures in epilepsy patients aged 12 and up. In addition, Daiichi Sankyo Company introduced vimpat tablets 50 mg and 100 mg in 2016 for supplementary therapy in the treatment of partial onset seizures with or without secondary generalisation in epilepsy patients.
Purchase this Report at Discount Of US $2000 Flat OFF – https://www.coherentmarketinsights.com/promo/buynow/1701
Antiepileptic Drugs Market – Competitive Landscape
Key players functioning in the global prosthetic liners market consists of Novartis AG, GlaxoSmithKline Plc, Johnson & Johnson Service, Inc., Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Sanofi S.A., Sumitomo Dainippon Pharma Co., Ltd., Mylan N.V., Bausch Health Companies Inc., and UCB Pharma Limited
Main points in Antiepileptic Drugs Market Report Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Global Antiepileptic Drugs Market Size Analysis from 2021 to 2027
11.6 COVID-19 Outbreak: Antiepileptic Drugs Industry Impact
Chapter 2 Global Antiepileptic Drugs Competition by Types, Applications, and Top Regions and Countries
2.1 Global Antiepileptic Drugs (Volume and Value) by Type
2.3 Global Antiepileptic Drugs (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Antiepileptic Drugs Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Antiepileptic Drugs Market Analysis
Chapter 6 East Asia Antiepileptic Drugs Market Analysis
Chapter 7 Europe Antiepileptic Drugs Market Analysis
Chapter 8 South Asia Antiepileptic Drugs Market Analysis
Chapter 9 Southeast Asia Antiepileptic Drugs Market Analysis
Chapter 10 Middle East Antiepileptic Drugs Market Analysis
Chapter 11 Africa Antiepileptic Drugs Market Analysis
Chapter 12 Oceania Antiepileptic Drugs Market Analysis
Chapter 13 South America Antiepileptic Drugs Market Analysis
Chapter 14 Company Profiles and Key Figures in Antiepileptic Drugs Business
Chapter 15 Global Antiepileptic Drugs Market Forecast (2021-2027)
Chapter 16 Conclusions
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
- CDN Newswire